Article Per Year (5 Year)
p-Index From 2021 - 2026
0.659
P-Index
This Author published in this journals
All Journal Jurnal Penyakit Dalam Indonesia
Syahidatul Wafa, Syahidatul
Unknown Affiliation
Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Mutation and Variant of Coronavirus Disease 2019 (COVID-19): Review of Current Literatures Susilo, Adityo; Jasirwan, Chyntia Olivia Maurine; Wafa, Syahidatul; Maria, Suzy; Rajabto, Wulyo; Muradi, Akhmadu; Fachriza, Ihza; Putri, Myranda Zahrah; Gabriella, Stacy
Jurnal Penyakit Dalam Indonesia Vol. 9, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Since March 2020, the Coronavirus Disease 2019 (COVID-19) pandemic has engulfed the world, including Indonesia, for nearly two years. SARS-CoV-2 has undergone several mutations during its evolution as a pathogen, resulting in various variants of global concern. Variants of this virus are suspected to impede the outbreak resolution and possibly causing the outbreak to spiral out of control. There is still considerable debate and research underway regarding the new SARS-CoV-2 variants. Rapid transmission mechanisms and widespread vaccination coverage have accelerated the virus’s mutation rate and resulted in numerous new variants. To date, this has resulted in the discovery of a new variant Omicron (B.1.1.529) in November 2021 in South Africa, which has since spread to 103 countries. Omicron is designated a Variant of Concern (VoC) due to its more powerful transmission than the previous variant. Although some information indicates that the symptoms associated with this variant are typically mild, the rapid transmission of Omicron can increase the next wave of COVID-19 cases. Additional research is required to determine transmissibility, pathogenesis, diagnosis, and proper management. As a result, we conducted an adjunct to studies on various COVID-19 mutations and variants until January 2022.
Puasa Ramadan dan Diabetes Melitus: Risiko, Manfaat dan Peluang Penelitian Tahapary, Dicky L; Wafa, Syahidatul; Harbuwono, Dante S.
Jurnal Penyakit Dalam Indonesia Vol. 8, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Prevalensi COVID-19 Derajat Berat dan Kritis saat Admisi pada Pasien Penyakit Reumatik Autoimun dan Faktor-Faktor yang Berhubungan Destini, Mulia; Ariane, Anna; Yulianti, Mira; Rizka, Aulia; Rinaldi, Ikhwan; Mansjoer, Arif; Maulahela, Hasan; Wafa, Syahidatul
Jurnal Penyakit Dalam Indonesia
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Patients with autoimmune rheumatic diseases are known to be more vulnerable to severe and critical infections, including COVID-19. Although it is no longer classified as a pandemic, SARS- CoV-2 infection still persists, and several surges of cases have been reported, including in Indonesia. To date, no data are available regarding the prevalence of severe and critical COVID-19 at admission in patients with autoimmune rheumatic diseases in Indonesia and the associated factors. This study aimed to determine the prevalence of severe and critical COVID-19 at admission in patients with autoimmune rheumatic diseases at Dr. Cipto Mangunkusumo National General Hospital, and to identify the associated factors. Methods. This was a cross-sectional study using secondary data from the medical records of patients with autoimmune rheumatic diseases confirmed with COVID-19 and hospitalized at Dr. Cipto Mangunkusumo National General Hospital between July 2020 and August 2024. Analyses were performed up to multivariate logistic regression to evaluate the association between predictor variables and severe and critical COVID-19 at admission. Results. Among 171 subjects, the majority were female (n=158). The median age was 31 years, ranging from 18 to 74 years. The prevalence of severe and critical COVID-19 at admission in patients with autoimmune rheumatic diseases was 41.5%. Routine corticosteroid use (adjusted prevalence ratio (aPR) 2.58; 95% CI 1.40–5.17; p=0.004), the presence of comorbidities (aPR 2.24; 95% CI 1.19–4.59; p=0.018), moderate–high disease activity (aPR 5.12; 95% CI 1.74–21.96; p=0.009), and combination immune-modifying therapy (aPR 1.79; 95% CI 1.06–3.17; p=0.034) were independently associated with severe and critical COVID-19 at admission in the final multivariate analysis. Conclusions. The prevalence of severe and critical COVID-19 at admission in patients with autoimmune rheumatic diseases was 41,5%. The associated factors were routine corticosteroid use, the presence of comorbidities, moderate–high disease activity, and combination immune-modifying therapy.
Co-Authors Adityo Susilo, Adityo Anna Ariane, Anna Ari F Syam Arif Mansjoer Aulia Rizka, Aulia Chyntia Olivia Maurine Jasirwan, Chyntia Olivia Maurine Dadang Makmun Dante S. Harbuwono Destini, Mulia Fachriza, Ihza Gabriella, Stacy Hasan Maulahela Ikhwan Rinaldi Mira Yulianti, Mira Muradi, Akhmadu Putri, Myranda Zahrah Suzy Maria Tahapary, Dicky L Wulyo Rajabto